Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.54 |
| ▸ | TUBB | P07437 | 5/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229888 | 0.88 | TSHR (0.59) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10674510 | 0.79 | TSHR (0.58) | NQO2ABCG2PDE4APDE4BPDE4C | |
| SCHEMBL374153 | 0.78 | ABCG2 (0.62) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Water SCHEMBL15135999 | 0.77 | ABCG2 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2127017 | 0.77 | MEN1 (0.61) | ABCG2MAPTMEN1KMT2AGAA | |
| SCHEMBL12327912 | 0.75 | MAPT (0.54) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27417353 | 0.75 | MAPT (0.54) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9859825 | 0.74 | TUBB4A (0.51) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3655501 | 0.74 | TUBB4A (0.48) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3022881 | 0.74 | TUBB1 (0.55) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| US-20020177723-A1 | Compounds and methods for the treatment of inflammatory and immune disorders | LEUKOSITE, INC. | 2002-11-28 | — | — | US | disclosed |
| US-6420392-B1 | PAF RECEPTOR ANTAGONISTS AND/OR BY INHIBITING THE ENZYME 5-LIPOXYGENASE. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6294574-B1 | THERAPY OF DISORDER CAUSED BY PLATELET ACTIVATION FACTOR BY TRANS-2-(5-N'-METHYL-N'-HYDROXYUREIDYLMETHYL)-3-METHOXY-4-P-CH LOROPHENYLTHIOETHOXPHENYL)-5-(3,4,5-TRIMETHOXPHENYL)TETRAHYDRO FURAN OR ITS SALT | CYTOMED, INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1123095-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0650485-B1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023071-A9 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE INC (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000023071-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5856323-A | PAF RECEPTOR ANTAGONISTS, INHIBITING THE ENZYME 5-LIPOXYGENASE | CYTOMED, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5741809-A | Compounds and methods for the treatment of cardiovascular inflammatory and immune disorders | CYTOMED, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1995018610-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5114961-A | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | MERCK & CO., INC. (US) | 1992-05-19 | — | — | US | disclosed |
| US-5010100-A | Skeletal muscular disorders, hydertensive agents, cardiovascular disorders | MERCK & CO. INC. (US) | 1991-04-23 | — | — | US | disclosed |
| US-4996203-A | Platelet-activating factor antagonists | MERCK & CO., INC. (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0402150-A1 | New 2,5-diaryl tetrahydrofurans and analogs therof as PAF antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0402151-A1 | New 2, 5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4977146-A | ANTICOAGULANT | MERCK & CO., INC. (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | ALOX5, ALOX5AP, ALOX15 | TUBB1 4469/4885TUBB4A 4397/4885TUBB 4588/4885 |
| US-20020177723-A1 | Compounds and methods for the treatment of inflammatory and immune disorders | LTB4R2, LTC4S, LTB4R | TUBB1 3859/4885TUBB4A 3266/4885TUBB 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.